Axepharma
Sources: the KBO register on 17-11-2026; the National Bank, 2025 annual accounts filed on 26-05-2026; the Belgian Official Gazette, latest deed of 16-12-2019.
Grounds
the facts the verdict rests on, each with its source- Axepharma made a profit in every financial year since 2020.Annual accounts 2020 to 2025 page 2
- Equity stands at €310,130, or 70.1% of the balance sheet total of €442,129.Annual accounts 2025 page 2
- Axepharma paid out €63,000 in dividends, 96% of the profit of 2025. Because of the dividend, solvency fell from 79.7% to 70.1%.Annual accounts 2025 page 2
- The 2025 accounts reached the National Bank 66 days before the end of the term.National Bank, filing of 26-05-2026 page 4
Representation
The signing rule is in the deed of 16-12-2019.
Articles of association, Belgian Official Gazette of 16-12-2019, deed 19348851
Ownership
founded Axepharma by deed of 16-12-2019. There is one other shareholder.
Deed of 16-12-2019
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €147,385 | €152,867 | €129,552 | €145,052 | €151,840 | |
| Operating result | €106,350 | €113,933 | €85,409 | €85,882 | €95,976 | |
| Net result | €67,606 | €69,445 | €49,132 | €58,188 | €65,629 | |
| Balance sheet at the closing date | ||||||
| Equity | €135,400 | €204,846 | €253,978 | €309,856 | €310,130 | |
| Debts | €100,539 | €84,391 | €76,531 | €78,910 | €131,999 | |
| Debts due after more than one year | €40,742 | €21,284 | €1,645 | - | - | |
| Debts due within one year | €59,797 | €63,106 | €74,886 | €77,160 | €130,494 | |
| Cash | €38,044 | €99,099 | €49,509 | €98,978 | €177,525 | |
| Balance sheet total | €235,940 | €289,236 | €330,509 | €388,765 | €442,129 | |
| Operations | ||||||
| Employees in full-time equivalents | 2.0 | 2.0 | 2.0 | 2.0 | 1.1 | |
| Ratios | ||||||
| Solvency | 57.4% | 70.8% | 76.8% | 79.7% | 70.1% | |
| Liquidity | 3.82 | 4.49 | 4.30 | 4.96 | 3.32 | |
Source: Annual accounts 2025, abbreviated format, filed on 26-05-2026 (2026-00120809); Annual accounts 2024, micro format, filed on 01-07-2025 (2025-00209307); Annual accounts 2021 to 2023, filed from 28-07-2022 to 31-07-2024 (2022-20236399, 2023-00319863, 2024-00321999).
The operating result of 2025 is 12% higher than in 2024.
Debts rose by €53,090 in 2025. A dividend stands among the debts on the balance sheet date until it is paid.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
Board, signature and ownership
Position on 17-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the deed of 16-12-2019.
Articles of association, Belgian Official Gazette of 16-12-2019, deed 19348851
Board
two directors in officeOwnership and group
Shareholders
founded Axepharma by deed of 16-12-2019. founded Axepharma by deed of 16-12-2019.
Deed of 16-12-2019
Events and comparison
Every event since the founding, newest first
Annual accounts 2025 filed, 66 days before the deadline.
NBB filingAnnual accounts 2024 filed, 30 days before the deadline.
NBB filingRegistered in the Peppol Directory. Reachable for e-invoices through 0208:0739549477.
Annual accounts 2023 filed. On the deadline day.
NBB filingWeakest financial year. The net result drops to €49,132, the lowest from 2020 to 2025. It recovers the following year.
FinancialAnnual accounts 2022 filed, 7 days late.
NBB filingHighest result from 2020 to 2025. The operating result of €113,933 and the net result of €69,445 are both a record.
FinancialEquity above €200,000. With a profit in every financial year since 2020, equity grows to €204,846.
FinancialAnnual accounts 2021 filed, 3 days before the deadline.
NBB filingEquity above €100,000. With a profit in every financial year since 2020, equity grows to €135,400.
FinancialAnnual accounts 2020 filed, 9 days before the deadline.
NBB filingIncorporation. Founding capital of €10,000, 1,000 shares. Founded by and . (director) and (director) appointed. Published on 16-12-2019.
Gazette, deed 19348851First establishment. Smedenstraat 73, Bruges.
Comparable companies, two years later
In July 2024, 26,977 companies had the same profile as Axepharma has now: micro, 5 to 10 years old, solvency 30% or more and a profit of 5% of the balance sheet or more. Two years later 94.8% were still trading, 3.6% had stopped another way and 1.6% had gone bankrupt.
In 2025, Axepharma had a higher net result than 61% of the 13,256 companies in the retail trade sector (NACE 47).
Other findings
Peppol
Reachable for e-invoices since 08-11-2024, under 0208:0739549477.
Sanctions lists
Staff
2 employees on 31-12-2025, 1.1 full-time equivalents on average over the year.
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 17-11-2026 | KBO 0739.549.477 |
| National Bank of Belgium | Annual accounts 2025, abbreviated format | 26-05-2026 | 2026-00120809 |
| National Bank of Belgium | Annual accounts 2024, micro format | 01-07-2025 | 2025-00209307 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 28-07-2022 to 31-07-2024 | 2022-20236399, 2023-00319863, 2024-00321999 |
| Belgian Official Gazette | Articles of association with the signing rule | 16-12-2019 | deed 19348851 |
| Peppol Directory | Registration for e-invoices | 08-11-2024 | 0208:0739549477 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 16-11-2026 | no match |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 16-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 16-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Payment terms. Supplier credit is the debt to suppliers divided by the year's purchases, times 365. Customer credit is the same for what customers still owe, against turnover.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.